首页> 美国卫生研究院文献>Iranian Journal of Basic Medical Sciences >The effect of nanomicelle curcumin sorafenib and combination of the two on the cyclin D1 gene expression of the hepatocellular carcinoma cell line (HUH7)
【2h】

The effect of nanomicelle curcumin sorafenib and combination of the two on the cyclin D1 gene expression of the hepatocellular carcinoma cell line (HUH7)

机译:纳米胶束姜黄素索拉非尼和两者的组合对肝癌细胞系(HUH7)cyclin D1基因表达的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Hepatocellular carcinoma (HCC) is one of the most significant health condition around the world. As the only curative therapies, liver transplantation and surgical resection are the clinical treatments of HCC. Due to the systemic toxicity and severe side effects of these treatments, it is vital to establish new therapeutic approaches. The present study aimed to compare cyclin D1 (CCN D1) gene expression in hepatocellular carcinoma cell line (HUH7) when it is treated with nanomicelle curcumin and sorafenib. The purpose was to identify toxicity risk and antioxidant activity of these drugs.
机译:肝细胞癌(HCC)是世界上最重要的健康状况之一。作为唯一的治疗方法,肝移植和手术切除是肝癌的临床治疗方法。由于这些疗法的全身毒性和严重的副作用,建立新的治疗方法至关重要。本研究旨在比较用纳米胶束姜黄素和索拉非尼治疗肝细胞癌细胞株(HUH7)中细胞周期蛋白D1(CCN D1)基因的表达。目的是确定这些药物的毒性风险和抗氧化活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号